Image source: The Motley Fool.

DATE

Wednesday, Aug. 12, 2026 at 5 p.m. ET

CALL PARTICIPANTS

• Vice President and Treasurer - Frank Vargo
• President and Chief Executive Officer - Joseph C. Papa Jr.
• Executive Vice President and Chief Financial Officer - Richard S. Lindahl

TAKEAWAYS

• Total Revenue -- $234.3 million, primarily reflecting the acceleration of medical countermeasure deliveries to the U.S. government.
• GAAP Net Loss -- $180.2 million, largely due to a $191.3 million non-cash impairment charge related to the naloxone asset group.
• Adjusted Net Income -- $30.9 million, representing a 134% improvement over the prior year period.
• Adjusted EBITDA -- $96.5 million, resulting in an adjusted EBITDA margin of 41%.
• Adjusted Gross Margin -- 58%, expanding 900 basis points year over year due to favorable product mix and higher volumes.
• Naloxone Product Revenue -- $52.4 million, declining 22% year over year because of unfavorable price-volume mix in U.S. public interest channels.
• Smallpox MCM Revenue -- $101.6 million, increasing 150% year over year driven by the timing of ACAM2000 deliveries.
• Other Product Revenue -- $54.1 million, primarily comprising sales of botulism antitoxin heptavalent to the U.S. government.
• Anthrax MCM Revenue -- $12.3 million, increasing 6% year over year behind a favorable pricing mix for international sales.
• Non-cash Impairment Charge -- $191.3 million, reflecting an updated assessment of expected future cash flows for the NARCAN asset group.
• Annualized Cost Savings -- approximately $40 million, expected from restructuring actions including site closures and lease exits.
• Workforce Reduction -- approximately 90 positions, representing part of the company's organizational restructuring to align with current needs.
• Building Sale Proceeds -- $6.4 million, resulting from the sale of an unutilized office building in Gaithersburg, Maryland.
• July Accounts Receivable Collections -- $145 million, improving operating cash flow and liquidity shortly after the quarter closed.
• Cash and Cash Equivalents -- $139.7 million as of June 30, 2026, down from $205.4 million at the end of 2025.
• Total Liquidity -- $190 million, including cash and availability under the company's asset-backed loan facility.
• Debt Repurchase Authorization -- $75 million, specifically targeted at repurchasing senior unsecured notes.
• Share Repurchases -- $9 million, representing the buyback of 1.1 million shares during the second quarter.
• 2026 Total Revenue Guidance -- $645 million to $675 million, revised downward from a previous range of $720 million to $760 million.
• 2026 Adjusted EBITDA Guidance -- $130 million to $150 million, reflecting lower commercial revenue expectations partially offset by cost savings.
• 2026 GAAP Net Loss Guidance -- $245 million to $225 million, accounting for non-cash impairment charges and restructuring expenses.
• Q3 2026 Revenue Guidance -- $110 million to $130 million, anticipating a step down following accelerated deliveries in the first half of the year.
• SG&A Expense -- $44.6 million, which management expects to represent 27% to 28% of total revenue for the full year.
• R&D Expense -- $9.2 million, focused on programs including TEMBEXA, Ebanga, and raxibacumab.
• Capital Expenditures -- $2.1 million, reflecting reduced development activities across the company's facilities.

Need a quote from a Motley Fool analyst? Email [email protected]

RISKS

• Lindahl stated, "recent developments in the naloxone market have led to increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group," noting that these factors necessitated a material non-cash impairment.
• Papa warned that while the company expects to maintain a leadership position, "we expect there will be some additional price pressures on the product" due to new nasal naloxone entrants.

SUMMARY

Management at Emergent BioSolutions Inc. (EBS +2.25%) reported second-quarter results that exceeded prior guidance despite facing increased competition in the naloxone market. The company announced an organizational restructuring plan intended to align resources with current market realities and generate significant annualized cost savings. While the medical countermeasure segment performed ahead of expectations due to accelerated U.S. government deliveries, management revised its full-year 2026 financial outlook downward to reflect pricing and volume pressures in the commercial segment. Strategic priorities remain focused on debt reduction, operational efficiency, and the development of core biodefense assets.

• Papa attributed the restructuring to a need to "align our resources with current business realities and prepare Emergent for 2027 and beyond."
• The company intends to collaborate with AI leaders to address "the potential risk of bioterrorism and improve biodefense response preparedness."
• Management noted the receipt of Saudi FDA approval for ACAM2000 and Singapore Health Sciences Authority approval to expand the vaccine's indication to include mpox.
• Papa stated that while competition is increasing, "the brand NARCAN itself is important" and the company believes it maintains over a 50% market share of the naloxone market.
• A new Growth organization was established to harmonize scientific discovery, clinical development, and commercial insight under one executive leader.
• The company authorized a $75 million debt repurchase program to address its senior unsecured notes following a term loan refinancing in April 2026.

INDUSTRY GLOSSARY

• Medical Countermeasures (MCM): Products such as vaccines and therapeutics used to treat or prevent diseases caused by chemical, biological, radiological, or nuclear agents.
• ACAM2000: A vaccine indicated for active immunization against smallpox and mpox disease.
• NARCAN: A brand-name naloxone nasal spray used for the emergency treatment of known or suspected opioid overdose.
• BAT (Botulism Antitoxin Heptavalent): A therapeutic for the treatment of symptomatic botulism following exposure to botulinum neurotoxin.
• Ebanga: A treatment for Ebola virus disease.
• TEMBEXA: An antiviral medication for the treatment of smallpox disease.
• Non-GAAP: Financial measures that exclude certain items, such as non-cash charges or one-time costs, to provide an alternative view of performance.
• Adjusted EBITDA: Earnings before interest, taxes, depreciation, and amortization, further adjusted for specific non-cash or non-recurring items.

Full Conference Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the Q2 26 Emergent BioSolutions Inc Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Frank Vargo, Vice President and Treasurer. Please go ahead.

Frank Vargo: Good afternoon, everyone. And thank you for joining us as Emergent discusses its operational and financial results for the second quarter of 2026. As is customary, today's call is open to all participants. it is being recorded. And is copyrighted by Emergent BioSolutions. In addition to today's press release, a slide presentation accompanying this webcast is available to all webcast participants. Turning to slide 2, During today's call, Emergent may make projections and other forward looking statements related to its business, future events, prospects or future performance.

These forward looking statements are based on our current intentions, beliefs and expectations regarding future events, Any forward looking statement speaks only as of the date of this conference call, And except as required by law, Emergent does not undertake to update any forward looking statement to reflect new information, events or circumstances. Investors should consider this cautionary statement as well as the risk factors identified in Emergent's periodic reports filed with the SEC, when evaluating these forward looking statements. During today's call, Emergent may also discuss certain non GAAP financial measures that include adjustments to GAAP figures to provide additional transparency regarding the company's operating performance. Please refer to the tables included in today's press release.

Turning to slide 3. The agenda for today's call includes remarks from Joe Papa, President and Chief Executive Officer who will provide an update on the company's transformation plan, business performance, and key highlights. Richard S. Lindahl, EVP and Chief Financial Officer, will then review the second quarter 26 financial results and provide an update on full year 2026 guidance. Joe Papa will conclude with a discussion of the company's key catalysts for growth followed by a question and answer session. Finally, for the benefit of those who may be listening to the replay of this webcast, this call was held and recorded on 08/05/2026. Since that time, Emergent may have made announcements related to topics discussed during today's call.

With that, I would now like to turn the call over to Joe Papa. Joe?

Joseph C. Papa Jr.: Thank you, Frank. Hello, everyone, and thank you for joining us to discuss Emergent's Second Quarter 26 Financial Results. This is Joe Papa, President and CEO of Emergent. And I am joined today by Richard S. Lindahl, our Chief Financial Officer. This afternoon, I will share updates on our multiyear transformation, our strong second quarter business performance and our continued work to protect and save lives. Following my remarks, Richard will detail our quarter 26 financial results and provide our updated 2026 guidance I will close the call with a discussion of our 2026 business outlook, and the catalysts we believe will enable growth as we continue to execute on our turnaround priorities.

Then we will open up the call for Q&A. I will now begin on Slide 5. For more than 25 years, Emergent has responded to complex and urgent public health threats with preparedness solutions and active response capabilities. Today, we believe Emergent is the leader in biodefense preparedness in naloxone, serving patients customers and government partners around the world. Our mission remains clear. To protect and save lives. That mission guides how we prioritize patient safety, quality, and compliance, and how we invest in the capabilities that matter most for our future. Our multiyear transformation plan continues to guide our business. We remain focused on improving operating performance advancing strategic transformation for long term growth and profitability.

Identifying growth opportunities aligned with our internal capabilities and continuing to strengthen the balance sheet. As an example, through a great team effort, we achieved strong second quarter results significantly ahead of consensus and exceeded our own internal expectations. However, we also experienced some changes in NLX at the end of the second quarter. On Slide 7, let me address the naloxone business directly. Since the NARCAN launch in 2016 and the OTC FDA approval in 2023, Emergent has maintained its leadership position and adapted to the evolving market landscape. However, recently, we saw 2 new nasal naloxone entrants.

Including a new 4 milligram over the counter approval on 06/16/2026, and a 10 milligram prescription agent that will launch in August 2026. and more aggressive pricing across the naloxone segment. These are changes in the signals we must proactively address. That said, opioid overdose deaths remain unacceptably high, with 45 thousand lives lost annually in The US our work as a trusted brand leader remains critical for communities across the US and Canada. As market dynamics change, we need to proactively get ahead of these issues.

Progressing to slide 8, as we navigate through our turnaround and broader transformation and also address the Naloxone business market dynamics, we are taking action to align our resources with current business realities and prepare Emergent for 2027 and beyond. Beginning today, we are implementing several restructuring actions intended to improve our overall cost structure. Keep Emergent efficient and nimble and align resources to the current needs of the organization. Our restructuring efforts are expected to yield annualized savings of approximately $40 million. These actions include a reduction in workforce of approximately 90 positions, the closure of 2 wet laboratories in Maryland, the sale of an unutilized office building for $6.4 million and exiting of a central warehouse lease.

Also, we have integrated growth under 1 team leader and establish a group where scientific discovery portfolio strategy, clinical development, commercial insight, and external innovation will all be harmonized. The bottom line, we are taking the steps now that are needed to ensure the future of Emergent as a strong and prosperous throughout our transformation journey. Before handing it over to Richard for a more detailed financial review, I would like to highlight our strong second quarter performance on Slide 10. Q2 revenue was $234 million significantly exceeding the high end of our guidance range coming in ahead of our internal expectations.

Year to date revenue was $390 million reflecting strong execution and acceleration of our MCM deliveries in Q2 through our ongoing collaborative partnerships with the U. S. Government. We delivered Q2 adjusted EBITDA of $97 million with a 41% margin, and year to date adjusted EBITDA was $132 million with a 34% margin. These results demonstrate the excellent focus execution of our teams have brought to the business. Finally, as we continue to focus on pursuing targeted business development, we are also responding to public health threats like Ebola, by initiating our Pan-Ebola Therapeutic Program.

We also advanced important regulatory activities during the quarter including the receipt of Saudi FDA approval for the ACAM2000 and the Singapore Health Sciences Authority approval to expand ACAM2000 to include the MPOXX indication. The MPOXX study in Africa, or MOSA, is also evaluating TEMBEXA, has over 100 patients enrolled in the study sponsor, Panthera, with Africa CDC and other partners are opening additional sites. Turning to Slide 11. Our MCM business remains core to Emergent's mission and is a key growth driver. We continue to support the US government and allied government partners with critical products and capabilities that help prepare for, respond to, and recover from serious public health threats.

Today, we announced that we are seeking to collaborate with AI leaders and partners to address the potential risk of bioterrorism and improve biodefense response preparedness. In Q2, MCM revenue was $168 million the highest second quarter revenue since 2020. We received multiple US government contract awards and international product orders, including a contract modification of $52.7 million for ACAM2000 and a $64.5 million contract modification for botulism antitoxin. Year to date, we have secured over 10 contract awards. International momentum is also building, and we continue to see the realities of our world becoming increasingly dangerous when Ebola virus is on the rise in Africa.

International MCM sales represent approximately 20% of our total first half 2026 MCM revenues, reflecting continued engagement with the US, and allied governments and the importance of bio preparedness in an increasingly dangerous world. Let me now hand the call over to Richard. Following Richard's comments, I will spend some time elaborating on our business outlook and growth catalyst.

Richard S. Lindahl: Thank you, Joe. Good afternoon, everyone, and thank you for joining our call today. We delivered a strong second quarter and first half of 2026 with revenue and adjusted EBITDA, exceeding both our internal expectations and the analyst consensus. We continue to advance key strategic priorities generated strong operating cash flow and maintained a solid cash position while also making the $50 million Ebanga investment milestone payment during the quarter. And we improved our capital structure with the April 2026 term loan refinancing which lowered interest expense, extended maturities, and enhanced our financial flexibility. Performance in our medical countermeasures segment remained very solid and consistent with our full year outlook even as we accelerated some deliveries into the second quarter.

In the commercial segment, recent developments in the naloxone market have led to increased competitive intensity with implications for our near to medium term outlook and the book value of our NARCAN asset group. As Joe highlighted, we have responded by implementing actions to drive greater efficiency and cost savings as we exit this year and prepare for 2027. We expect these restructuring actions to generate approximately $40 million in annualized net savings and other improvements, partially offset by approximately $11 million of cost to achieve. We also executed a transaction to sell our underutilized building in Gaithersburg, Maryland for approximately $6 million.

In light of the increasingly competitive landscape for NARCAN, we recorded a noncash impairment charge of approximately $191 million in the second quarter. This accounting adjustment reflects our updated assessment of the product expected future cash flows in the context of current market dynamics. Including pricing and competitive factors. Importantly, this charge is noncash and does not affect our cash position, liquidity, operating cash flow or adjusted EBITDA. It does, however, reduce our GAAP net income for the quarter is an important factor in understanding the year over year comparison. Turning to slide 13. Our second quarter results exceeded expectations and reflect continued progress on execution.

Total revenue for the second quarter of 26 was $234 million which came in above the $185 million high end of our prior Q2 revenue guidance. This outcome was primarily driven by our continued strong partnership with the U. S. Government which resulted in the acceleration of medical countermeasure deliveries into Q2. Adjusted EBITDA for the quarter was $97 million representing a 41% adjusted EBITDA margin compared with $33 million and a 23% margin in the prior year period. Adjusted gross margin was 58%, up from 49% in the second quarter of 2025, largely driven by product mix and overall volume. Operating expenses were $54 million in the quarter, down approximately $2 million year over year.

Demonstrating continued cost discipline across the business. Moving on to Slide 14, we highlight the notable revenue elements driving second-quarter comparison. MCM revenue was the primary contributor to the year over year increase, supported by accelerated deliveries and contract activity related to ACAM and BAT. Commercial revenue continues to reflect NARCAN's market leadership position while year over year performance was affected by new competitive pressure and continued pricing and volume dynamics. Turning to slide 15. Year to date results were also quite strong. Total revenue was $390 million for the first 6 months of 2026, up from $363 million in the prior year period. Driven primarily by accelerated MCM deliveries and strong execution with the U.S. and international government customers.

Adjusted EBITDA was $132 million year-to-date, representing a 34% margin compared with $112 million and a 30% margin in the prior year period. Adjusted gross margin was 56%, up 100 basis points year over year, reflecting the benefit of product mix and disciplined operational execution. Moving to Slide 16. The notable year-to-date revenue elements show the same dynamics we saw in the quarter. MCM revenue was the primary driver of the year over year increase, supported by the timing of product deliveries accelerated contract awards, and meaningful international sales. Commercial revenue continues to reflect NARCAN's strong leadership position while year to date performance has been pressured by a more competitive naloxone market.

Overall, the first half reflects strong MCM performance offsetting pressure in the commercial portfolio. On Slide 17, we highlight continued stability in our financial metrics. We ended the second quarter with $140 million of cash and $190 million of total liquidity. While cash has declined versus the prior year period, the business continued to generate significant operating cash flow while also absorbing the $50 million Ebanga investment milestone payment during the quarter. In addition, we have already received $145 million of cash through July from the $190 million accounts receivable balance at June 30, which further improves our operating cash flow and liquidity.

Gross debt was $590 million as of June 30, 2026, compared with $700 million in the prior year. Net debt was $450 million and our net leverage ratio remained stable year over year at 1.9x trailing 12-month adjusted EBITDA. On Slide 18, turning to capital allocation, our priorities remain focused on strengthening the business and creating long term shareholder value. We completed the April 2026 term loan refinancing establishing a new $150 million term loan with maturity extended to 2031 reduced interest rates, and enhanced operating and financial flexibility. In addition, our board authorized a new $75 million debt repurchase program And as previously mentioned, we have a $50 million share repurchase program through March 2027.

During the second quarter, we repurchased 1.1 million shares for approximately $9 million, bringing year to date repurchases to 1.9 million shares for $18 million. As of quarter end, $37.5 million remained available under the authorized share repurchase program. We continue to balance debt reduction, disciplined share repurchases, and investments in international MCM growth, internal R&D, including the Ebanga program, and business development opportunities. Turning to slide 19, we have updated our revenue and profitability guidance.

We are revising full-year 2026 total revenue guidance to a range of $645 million to $675 million, compared with our prior range of $720 million to $760 million The revision primarily reflects lower expected commercial revenue in the second half of the year, driven by increased competitive pressure in NARCAN, as well as continued pricing and volume pressure across the naloxone market. For MCM, we continue to expect contributions from U. S. Government procurement and sales, with the first half benefit from accelerated deliveries already reflected in our year to date results. We are also revising our profitability outlook to reflect updated revenue expectations the anticipated impact of restructuring actions and the NARCAN noncash impairment charge.

Our GAAP net loss guidance is now expected to be within a range of negative $245 million to negative $225 million which includes the effect of noncash items and restructuring related expenses. Adjusted net income guidance is now expected to be $10 million to $30 million We are revising adjusted EBITDA guidance to $130 million to $150 million compared with our prior range of $155 million to $175 million At the midpoint, the adjusted EBITDA reduction is substantially less than the revenue reduction, because the lower revenue outlook is partially offset in 26, by the impact of the cost savings initiative announced today, along with continued operating expense discipline.

We are also revising adjusted gross margin guidance to 42% to 44% reflecting the expected mix impact from lower commercial revenue. For the third quarter, we expect total revenue to be between $110 million and $130 million Q3 outlook reflects an anticipated step down following the accelerated MCM deliveries in the first half, as well as continued commercial pressure from the evolving naloxone marketplace. Even with the lower revenue outlook, we remain focused on cash generation, disciplined capital management and execution of our cost savings program to support profitability and liquidity through the balance of 2026. In summary, Q2 was a strong quarter for Emergent and capped a solid first half of the year.

We exceeded the high end of our Q2 revenue guidance, delivered EBITDA of $97 million with a 41% margin and generated strong operating cash flow. We ended the quarter with $140 million of cash which increased significantly in early Q3 through accounts receivable collections, And during the quarter, we continued to execute our capital management priorities. Following the April 2026 term loan refinancing we have enhanced financial flexibility through extended maturities, lower interest expense, and improved covenant flexibility. We will continue to demonstrate financial discipline as we sustain our current business pursue growth opportunities and create shareholder value over time.

And with that, I would like to turn the call back over to Joe to discuss our business outlook and growth catalyst before we go into Q&A. Joe?

Joseph C. Papa Jr.: Frank you, Richard. Turning to Slide 21, I would like to write context around our business outlook and the catalysts we believe can enable growth from 2026 and beyond. Our growth outlook is focused on 4 principal areas: First, expanding international MCM orders and opportunities Second, launching additional line extensions for the naloxone business, including the NARCAN nasal spray carrying case, including the in the multipack configurations. Third, driving organic growth through internal R&D programs, including TEMBEXA, Ebanga and raxibacumab. And fourth, accelerating growth through selective external business development opportunities that are value accretive. Additionally, as I previously mentioned, we are unifying R&D and business development into the growth organization.

Which we believe will help us make faster, more informed, portfolio decisions and allocate capital with greater discipline. Turning to Slide 22. Near term pipeline and current asset strategy is focused on maximizing the value of programs where Emergent has differentiated experience, clear mission alignment, and the potential to support sustainable growth. The important note here is that our pipeline is about focusing our resources on assets and programs where Emergent can lead or capabilities matter and where we can continue to help protect and save lives against public health threats. Now moving to our summary on slide 23.

While Emergent is continuing to execute on its multiyear transformation plan, we are taking decisive action now to address NARCAN business realities prepare the company for 2027, and beyond, and remain focused on our mission to protect and save lives. We are restructuring our business operation to improve overall cost structure, drive efficiencies and align resourcing to the current needs of the organization. Our MTM business continues to support The U. S. And international preparedness, and our Naloxone business continues to deliver on Emergent's mission to protect and save lives. We remain committed to patient safety, quality and compliance across the enterprise while pursuing growth initiatives in creating long term value for shareholders.

With that, I look forward to your question. Operator, if we can please open the line for questions.

Operator: Thank you. At this time, we will conduct the question and answer session. As a reminder, to ask a question, you will need to press *11 on your telephone and wait for your name to be announced. To withdraw your question, please press *11 again. Please stand by while we compile the Q&A roster. Our first question comes from the line of Raghuram Selvaraju of H.C. Wainwright & Co. Your line is now open.

Raghuram Selvaraju: Thanks very much for taking our questions. Firstly, with respect to the NARCAN situation, I was wondering if you could provide us with some additional granularity on any potential initiatives that you think are likely to be particularly effective in, A, slowing the pace at which NARCAN sales might erode. And b, potentially leverage the brand recognition that you have in order to position the franchise more effectively as effectively the key line of defense against next gen fentanyl analogs, which as I understand are significantly more addictive and more likely to be fatal. than fentanyl itself.

Secondly, I was wondering if you could just give us some more insight into your strategic thinking behind the reorientation of the company away from what sounds like basic R&D and how you anticipate redeploying those resources, particularly with potentially greater focus going forward on strategic in licensing and asset acquisition. And then lastly, I was wondering if you could give us a sense of given the fact, I think you said this multiple times in your prepared remarks, that we are increasingly living in a more and more dangerous world, whether you are seeing any emergent trends in MCM contract procurement demands outside of the United States. Thank you.

Joseph C. Papa Jr.: Sure. A lot of good questions there. I will take them 1 at a time, make sure I answer all of them. On the NARCAN initiatives, yes, absolutely we are looking at things to continue to keep the share we have today and potentially grow that share. We are looking at, obviously, number 1, the brand NARCAN itself is important. We have that brand name. When you are looking at the opportunities that face the marketplace. Having the brand name NARCAN is very important that we have had a chance to talk to consumers about that. They obviously recognize the importance of the NARCAN brand name. Number 2, as the market leader, we are continuing to bring out new innovation.

That new innovation we bring out includes things like the carrying case that is perfect for those students that are college students that clip it onto their back pack as an example. We are also looking at multi packs where we are putting additional NARCAN together to make it easier for the high user first responders who are high-volume users have the NARCAN available. And packs beyond just the 2 nasal sprays in 1 kit. As an example, just bringing out new innovation, bringing out what we are doing not only with the carrying case, but also the multipacks, but also the wall kits that we have that we are trying to get additional exposure for.

So those are the innovation things that we are doing beyond the brand name. And then finally, to be clear, we are still the market leader. We still have, we believe, over a 50% market share of the naloxone market. Having said that, though, we recognize with additional competition we expect there will be some additional price pressures on the product. that is why we made some of the decisions we talked about today. But we clearly believe NARCAN will continue to be the gold standard here, and we are prepared for that. But we wanna make sure we are looking at realistic what we think the numbers and what the issues are for NARCAN.

From a pricing pressure point of view with the knowledge that we have 2 new competitors coming into the space. On the second question, on the R&D side, I would say the answer to that is that we are looking at R&D still being pivotally important to us. We are continuing to still invest behind products like TEMBEXA, products like Ebanga, products like rexibacumab. We are continuing to look, as I mentioned in my comments, what can we do in Africa to do the MOSA trials to get some additional data on TEMBEXA and its benefits in mPOXX. So we are going to continue to invest in R&D to be clear.

We think, however, by putting the decisions into 1 group, where we bring the external business development and the internal R&D projects together into 1 decision maker, we will have the ability to make faster decisions better allocation of capital to the future pipeline opportunities and that is where we think we will get better return on investment for our shareholders going forward.

But to be clear, there is still going to be all the efforts we need on the R&D side to ensure we are going to have the appropriate decision making and just we think we can make faster, better decisions by putting together this 1, let's call it a chief of growth for the company to help us to make those decisions quickly. And focused on all the right return on investment metrics and trying to continue to advance our mission. On the question of the increasingly dangerous world, the answer to that is, are we seeing things, absolutely, correctly we are. We are hearing from governments around the world. What some of the issues are.

Some of you may have seen recent articles back going back into June where some of the AI CEO leadership are specifically writing letters of concern that AI could be utilized by bad actors to create new pathogens, pathogens that could be very, very chaotic and cause additional problems. We intend, as we put out a release today, to collaborate with the AI leadership to make sure that we are going to be front and center there on helping governments around the world to prepare for the potential activities that could happen through AI that could expedite bad actors creating pathogens that are problematic.

So we are absolutely as a leader in this area of medical countermeasure preparedness wanna be up front and center coordinating all the activities based on our experience. So those are the things that we think are important. We are going to continue to move forward and make progress with those because it is an increasingly dangerous world out there. Operator, next question.

Operator: Thank you. 1 moment for our next question. Our next question comes from the line of Jessica Fye of JPMorgan. Your line is now open.

Jessica Fye: Hey, guys. Good afternoon. Thanks for taking our questions. First, just on the kind of financial picture. It seems like other revenue was a key driver of year over year revenue growth in the first half. Can you outline just what is in there and how sustainable that is? And then for NARCAN, can you elaborate on what you are seeing in the naloxone market a little more specifically and talk about what your latest price and volume expectations are for NARCAN for the rest of this year? And longer term? And then lastly, sorry. Third question.

As it relates to the revenue guidance update, should we take that as entirely NARCAN related Was there any, say, upside from other business lines being more than offset by the NARCAN headwinds? Just want to kind of better understand what is below the surface there. Thank you.

Joseph C. Papa Jr.: So Hi, Jessica. Thanks for the question. On the other revenue, the biggest driver there is our BAT product our botulism antitoxin, and we had a significant delivery that occurred in the second quarter that really drove that year over year increase. The question of naloxone and where we are with the market and pricing. So what is out there in the market? The market's still a strong market in terms of what we are seeing in terms of unfortunately, 45 thousand people still dying because of opioid overdoses. So we still think the market need is there. We still are preparing to be out there with our units with NARCAN out there.

Having said that, though, we have seen competitive price pressures. We think the correlation of the new entrants and people preparing for new entrants to make sure that they can hold on to their share is, as with other generic companies, when they come in, to compete with the brand, they will look at price as an option to try to get some incremental share. We just want to make sure that we are prepared. I mean, to be clear, NARCAN is up versus the first quarter. So we did see it grow over the first quarter.

However, as we thought about the remainder of this year, and going into next year, we wanted to be prepared knowing what we have seen with other markets when additional generic players show up into the market. So that was the logic and how we thought about it for the rest of this year. And into next year. But we do expect to see additional price erosion, to be clear. We think the market's going to be should be flat maybe in terms of total naloxone units should be relatively flat, somewhere around that area. And we will obviously continue to look to maintain a leadership position in terms of market share for our NARCAN business.

The last question you asked was about the guidance. Richard, do you want to take that?

Richard S. Lindahl: Yes. Thank you. So the biggest driver of the change in our guidance is, in fact, that commercial segment or the view on naloxone revenue for the year. As we had previously guided for medical countermeasures, we thought it would be flat to slightly down on the year. That really our view really has not changed. For that segment. But for the factors that Joe highlighted just now and earlier on the call, we do see lower overall commercial revenue driven by naloxone for the balance of the year and for the full year. Thank you for the question, Jessica.

Joseph C. Papa Jr.: Operator, any additional questions?

Operator: Yes. Thank you. 1 moment for our final question. Our next question comes from the line of Alex Kelsey of Wells Fargo. Your line is now open.

Alex Kelsey: Hey, guys. appreciate you taking the questions. I will layer mine in sequential order as well. Just on the July comment about AR was that through a securitization program, or is that just collecting AR in normal course then regardless of the mechanism, you know, pro forma, all else equal, am I correct to think that cash, you know, pro forma is closer to, you know, the $140 million plus $145 million, so $285 million. that is number 2.

And then number 3, the comment on the $75 million debt repurchase authorization Am I safe to assume that would be targeted at the senior notes, or is there any reason that you would look to address the new term loan before the bonds?

Richard S. Lindahl: Thanks, Alex. Appreciate the questions. The collection of the $145 million is all from accounts receivable related to deliveries that occurred in the second quarter and that were in the balance as of the end of the second quarter. It is not related to a securitization or any other kind of financing facility. it is just pure, you know, working capital, accounts receivable, collection. As far as the impact on cash flow, yes, that certainly flows through to the cash balance. Obviously, there is some expenses as we come through the month, but safe to assume that a very meaningful portion of that, you know, flowed through to our cash balance as of the end of July.

And then finally, the $75 million authorization is specifically to repurchase the senior unsecured notes. And so that there will be a little more detail on that in the 10 Q when we file that. Alright.

Alex Kelsey: And if I am still on the line, regard to the $40 million cost savings, any sense of timing as to when we should expect that to be realized and annualized in the numbers?

Joseph C. Papa Jr.: Sure. We are going to start now. As I mentioned on the call, in terms of that realization, obviously, the full run rate of that would be in a full year of 2027, but we are starting now. We will pick up some in 2026, but the full run rate of a $40 million would be in 2027 and beyond. Great. Thank you very much. Operator, any other question?

Operator: That was the final question. So this concludes the question and answer session. I would now like to turn it back over to Joseph Papa for closing remarks.

Joseph C. Papa Jr.: All right. Well, thank you, everyone, for joining us today Please note an archived version of today's webcast as well as a PDF version of the slides used during today's call will be available later today and accessible through our Investors landing page on the company website. Thank you again for joining us. We look forward to speaking to you all in the near future. Frank you, everyone. Goodbye.

Operator: Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.